Edition:
India

Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

1.38USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.38
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
779,833
52-wk High
$1.77
52-wk Low
$0.73

Latest Key Developments (Source: Significant Developments)

Novavax CEO Stanley Erck reports open market purchase of 100,000 co's common shares
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Novavax Inc :Novavax Inc says CEO Stanley Erck reports open market purchase of 100,000 co's common shares at average price of $1.13per share on november 9 - sec filing.  Full Article

Novavax reports Q3 loss per share $0.15
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Novavax Inc ::Novavax reports third quarter 2017 financial results.Q3 loss per share $0.15.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Q3 revenue $8.4 million versus $3.2 million.Q3 revenue view $6.4 million -- Thomson Reuters I/B/E/S.  Full Article

Novavax Q3 loss per share $0.15
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Novavax Inc ::Novavax reports third quarter 2017 financial results.Q3 loss per share $0.15.Q3 revenue $8.4 million versus $3.2 million.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Q3 revenue view $6.4 million -- Thomson Reuters I/B/E/S.Novavax - ‍as of Sept 30, 2017, co had $172.6 million in cash, cash equivalents and marketable securities, compared to $235.5 million as of Dec 31, 2016​.  Full Article

Novavax announces leadership change
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Novavax Inc ::Novavax announces leadership change.Novavax Inc - ‍Barclay Phillips has submitted his resignation as senior vice president, chief financial officer (CFO) and treasurer​.Novavax Inc - ‍Erck will act as interim CFO pending completion of a search for a new chief financial officer​.  Full Article

Novavax Q2 loss per share $0.29
Wednesday, 10 Aug 2016 

Novavax Inc : Novavax reports second quarter 2016 financial results . Q2 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S . Q2 revenue fell 82 percent to $2.5 million . Q2 loss per share $0.29 . Q2 revenue view $8 million -- Thomson Reuters I/B/E/S .Says research and development expenses increased 134% to $64.9 million in q2 of 2016, compared to $27.7 million for same period in 2015.  Full Article

FDA grants fast track designation to Novavax' RSV F vaccine
Wednesday, 25 May 2016 

Novavax Inc :U.S. FDA grants fast track designation to Novavax' RSV F vaccine for older adults.  Full Article

Novavax Announces Closing of $300 Million Offering of Convertible Senior Notes Due 2023
Saturday, 30 Jan 2016 

Novavax, Inc:Says closing of its previously announced offering of $300 million aggregate principal amount of convertible senior unsecured notes that will mature on February 1, 2023 (the Notes).Under the purchase agreement, the initial purchasers may exercise their option to purchase up to an additional $30 million aggregate principal amount of the Notes solely to cover over-allotments any time before February 24, 2016.Citigroup and J.P. Morgan acted as joint book-running managers of the offering. Piper Jaffray and Guggenheim Securities acted as Co-Lead Managers.Notes bear cash interest at a rate of 3.75%, payable on February 1 and August 1 of each year, beginning on August 1, 2016.The Notes are not redeemable prior to maturity and are convertible into shares of Novavax common stock.The initial conversion rate for the Notes is 146.8213 shares of Novavax' common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $6.81 per share of Novavax' common stock.The net proceeds of the offering were approximately $291 million, after deducting the initial purchasers' discounts and commissions, but prior to deducting estimated offering expenses.Novavax used approximately $34.7 million of the net proceeds from the offering to pay the cost of the previously announced capped call transactions.  Full Article

Novavax announces proposed offering of $200 mln of convertible senior notes due 2023
Monday, 25 Jan 2016 

Novavax Inc:Announced that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior unsecured notes that will mature on February 1, 2023.Intends to use the net proceeds from the offering for the advancement of its clinical-stage vaccine candidates.  Full Article

BRIEF-Novavax Q3 loss per share $0.15

* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S